Drug Trial Radar · NCT00699374
Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
Last checked: Nov 19, 2026Latest source record: Jan 14, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,075
Actual
Start
Jul 2008
Primary completion
Dec 2011
Study completion Dec 2011
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jun 18, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the efficacy and safety of sunitinib (Arm A), given at 37.5 mg orally once daily, compared to sorafenib (Arm B), given orally at 400 mg twice daily, in patients with inoperable liver cancer. A total number of 1200 patients will be enrolled, 600 on Arm A and 600 on Arm B. Study treatment may be adjusted based on patient tolerance. and will be given until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. After discontinuation of study treatment, patients will be followed up in order to collect information on further antineoplastic therapy and survival.
Conditions
- Carcinoma, Hepatocellular
Interventions
sunitinib malateDrug
sunitinib capsules at starting dose of 37.5 mg PO daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sunitinib dosing interruptions and/or reductions are allowed based on patient tolerability.
sorafenibDrug
sorafenib tablets at starting dose of 400 mg PO twice daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sorafenib dosing interruptions and/or reductions are allowed based on patient tolerability.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Baseline, every 4 weeks during treatment, every 8 weeks posttreatment up to Week 150
Locations
171 sites in 23 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Fountain Valley, California
Pfizer Investigational Site
La Jolla, California
Pfizer Investigational Site
La Jolla, California
Pfizer Investigational Site
Orange, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
Miami, Florida
Pfizer Investigational Site
Ringgold, Georgia
Pfizer Investigational Site
Iowa City, Iowa
Pfizer Investigational Site
Crestview Hills, Kentucky
Pfizer Investigational Site
The Bronx, New York
Pfizer Investigational Site
Cincinnati, Ohio
Pfizer Investigational Site
Cincinnati, Ohio
Pfizer Investigational Site
Cincinnati, Ohio
Pfizer Investigational Site
Cincinnati, Ohio
Pfizer Investigational Site
Cincinnati, Ohio
Pfizer Investigational Site
Cincinnati, Ohio
Pfizer Investigational Site
Fairfield, Ohio
Pfizer Investigational Site
Hamilton, Ohio
Pfizer Investigational Site
Chattanooga, Tennessee
Pfizer Investigational Site
Franklin, Tennessee
Pfizer Investigational Site
Gallatin, Tennessee
Pfizer Investigational Site
Hermitage, Tennessee
Pfizer Investigational Site
Hixson, Tennessee
Pfizer Investigational Site
Lebanon, Tennessee
Pfizer Investigational Site
Murfreesboro, Tennessee
Pfizer Investigational Site
Nashville, Tennessee
Pfizer Investigational Site
Nashville, Tennessee
Pfizer Investigational Site
Nashville, Tennessee
Pfizer Investigational Site
Nashville, Tennessee
Pfizer Investigational Site
Smyrna, Tennessee
Pfizer Investigational Site
Mechanicsville, Virginia
Pfizer Investigational Site
Midlothian, Virginia
Pfizer Investigational Site
Richmond, Virginia
Pfizer Investigational Site
Richmond, Virginia
Pfizer Investigational Site
Seattle, Washington
Pfizer Investigational Site
Concord, New South Wales, Australia
Pfizer Investigational Site
Elizabeth Vale, South Australia, Australia
Pfizer Investigational Site
Woodville South, South Australia, Australia
Pfizer Investigational Site
Melbourne, Victoria, Australia
Pfizer Investigational Site
Parkville, Victoria, Australia
Showing 40 of 171 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.